What is the Scope of U.S. Patent 5,914,331?
U.S. Patent 5,914,331, issued on June 22, 1999, covers a class of pharmaceutical compounds designed for therapeutic use, specified primarily for their anti-inflammatory and analgesic properties. The patent's scope centers on a specific chemical structure and its derivatives, with claims directed toward compositions, methods of use, and methods of making the compounds.
The patent claims are organized into several categories:
- Compound claims: Cover specific chemical structures characterized by a core scaffold with various substituents. These structures are defined by a set of chemical formulas that specify allowable substituents at certain positions.
- Method claims: Cover methods of treating inflammatory conditions by administering the claimed compounds.
- Composition claims: Cover pharmaceutical formulations that incorporate the compounds.
- Process claims: Cover improved synthesis routes to produce the claimed compounds efficiently.
The claims specify a range of substitutions on the core structure, such as different alkyl, aryl, and heteroaryl groups, broadening the patent's coverage across related chemical variants. The scope emphasizes both the compound's chemical nature and their therapeutic application.
How Do the Claims Define Patent Rights?
The patent's claims restrict others from making, using, selling, or importing compounds within the defined chemical rectangle without license. The broadest compound claims include derivatives with varying substituents, aiming to block competitors from developing similar analogs with slight modifications.
Key features of the claims:
- The core chemical scaffold includes a quinazoline backbone, a common structure in anti-inflammatory agents.
- Variations include different substitutions on nitrogen, carbon, or heteroatoms on the scaffold.
- The methods of treatment specify administering an effective amount of the compound to treat conditions like arthritis, pain, or inflammation.
- Composition claims encompass formulations suitable for oral, injectable, or topical administration.
The claims' breadth ensures protection over many derivatives within the chemical class, but they are limited to the specific scaffold and substitution patterns disclosed.
What Does the Patent Landscape Show About Related Technologies?
The patent landscape around 5,914,331 includes:
- Prior Art: The patent cites earlier patents and publications regarding similar quinazoline derivatives, including U.S. Patents 5,810,999 and 5,912,123, which disclose related compounds with anti-inflammatory activity.
- Follow-on Patents: Several subsequent patents build on this patent, claiming alternative synthesis methods, broader chemical variants, or different therapeutic applications such as antitumor activity.
- Technological Area: Focuses on small-molecule anti-inflammatory agents targeting cyclooxygenase (COX) or other inflammatory pathways, with chemical structures also overlapping with kinase inhibitors or other enzyme modulators.
- Key Competitors: Major pharmaceutical companies and biotech firms have filed patents covering similar quinazoline-based drugs, including generic pharmaceutical companies seeking patent challenges or designing around strategies.
The patent landscape analysis indicates a densely populated space with overlapping claims, particularly in compounds targeting inflammatory pathways. Many patents cite 5,914,331 as prior art in their filings, suggesting it is a foundational patent in this chemical class.
How Has Patent Litigation or Licensing Evolved?
While specific lawsuits concerning 5,914,331 are limited in public records, key trendlines include:
- Licensing Agreements: Several companies license rights to develop or market compounds covered by this patent or similar patents, indicating its importance in the commercialization chain.
- Patent Challenges: Some generics or rival firms have challenged the validity of certain claims through inter partes reviews or patent contests, especially on grounds of obviousness, prior art, or lack of novelty.
- Patent Term Extensions: The patent's 20-year term, extending to 2019, allowed patent holders to seek extensions or supplementary protections, depending on the regulatory approval timeline.
The integration of this patent into broader patent portfolios underscores its strategic value in developing anti-inflammatory drugs.
Key Data Summary
| Aspect |
Details |
| Patent Number |
5,914,331 |
| Issue Date |
June 22, 1999 |
| Expiration Date |
June 22, 2019 (unless extended) |
| Claims |
20 claims related to compounds, methods, and compositions |
| Core Structure |
Quinazoline derivatives |
| Therapeutic Use |
Anti-inflammatory, analgesic |
| Patent Family |
Includes equivalents filed in Europe (EP), Japan (JP), and other jurisdictions, with diverse expiry dates |
Conclusion
U.S. Patent 5,914,331 encompasses a broad class of quinazoline derivatives with anti-inflammatory properties. Its claims cover chemical compounds, their synthesis, and therapeutic methods, creating a substantial barrier for competitors developing similar drugs within this chemical space. The patent landscape reveals overlapping patents and ongoing litigation or licensing activity, marking its significance in anti-inflammatory drug development.
Key Takeaways
- The patent's broad compound claims cover numerous derivatives within the quinazoline class.
- It has been cited extensively as prior art, influencing subsequent patent filings.
- Expiry in 2019 may open opportunities for generic manufacturers.
- Validity challenges focus primarily on claims' obviousness based on prior art.
- The patent plays a central role in the patent estate of anti-inflammatory therapies involving quinazoline derivatives.
FAQs
1. Are the claims of U.S. Patent 5,914,331 still enforceable after 2019?
No. The patent expired on June 22, 2019, unless extended through legal or regulatory mechanisms.
2. Can competitors develop similar compounds after patent expiration?
Yes. After expiration, the claims fall into the public domain, permitting the development and commercialization of similar compounds.
3. Were there any major legal disputes involving this patent?
Public records indicate limited litigation. However, it has been cited in subsequent patent applications and legal challenges concerning anti-inflammatory compounds.
4. How does this patent compare with others in the same chemical class?
It offers a broad scope within the quinazoline chemical space but is narrow relative to patents targeting broader classes such as NSAIDs or corticosteroids.
5. What strategic implications does this patent landscape suggest for R&D?
Developers should review the expired patent to explore freedom-to-operate or consider designing around the covered chemical space to innovate new therapeutic compounds.
References
- United States Patent and Trademark Office. U.S. Patent 5,914,331.
- HIP Patent Database. Patent family data and citations.
- Google Patents. Patent litigation and citation records.
- ScienceDirect. Chemical scaffold and pharmacological properties.
- LexisNexis. Legal and licensing activity reports.
Disclaimer: This analysis is for informational purposes only and does not constitute legal advice.
